NEW YORK, Nov 27 – Qiagen and Luminex have agreed to jointly develop consumable kits and assays using Luminex’s Labmap technology, the companies announced Monday.

Under the agreement, Qiagen will market the assay detection products beginning in the third quarter of 2001. Luminex has received an upfront payment for the Labmap technology, and will receive future royalty payments from Qiagen based on the sale of kits and reagents.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.